Business Wire

MINDEROO-FOUNDATION

9.5.2022 08:23:07 CEST | Business Wire | Press release

Share
Global Plastic Watch: Satellite Eyes Pinpoint Waste From Space to Reduce Ocean Pollution

A cutting-edge new tool developed by Minderoo Foundation has identified thousands of waste sites across 25 countries for the first time using advanced satellite data technology and machine learning to measure piles of plastic waste from space.

Global Plastic Watch (globalplasticwatch.org ) is a tool which combines earth observation with artificial intelligence to create the first-ever near-real-time high-resolution map of plastic pollution. This is the largest open-source dataset of plastic waste across dozens of countries. The aim of the tool is to help authorities to better manage plastic leakage into the marine environment.

Global Plastic Watch uses remote sensing satellite imagery from the European Space Agency and a first-of-its-kind machine learned model created in collaboration with award winning Digital Product Agency for the Environment, Earthrise Media . The tool is able to determine the size and scale of land-based plastic waste sites, a major factor in fueling the growing problem of plastic pollution of the world’s rivers and oceans.

The data gathered provides a historical first and authoritative insight into one of the world’s most intractable environmental challenges – a deluge of plastic pollution which is threatening the oceans, harming communities, marine life, animal and human health. By using it, governments, industry and communities can evaluate and monitor the risk of land-based plastic waste sites, as well as prioritise investments in solutions.

The countries mapped so far include all of South-East Asia, Australia, and the countries identified by research published in Science Advances as accounting for high rates of plastic emissions into the ocean.

Dr Andrew Forrest AO, Chairman and Co-Founder of the Minderoo Foundation described data and transparency as important tools to fight plastic waste, and until now, it has been difficult to effectively identify and measure plastic waste build-up in a systematic, standardised way.

“Generally, the world has no idea how dangerous plastic waste is to the organic environment, particularly humans. The destination for every piece of plastic is nano-plastic, which has both poisonous and cutting attributes able to mutilate cells and even penetrate the human blood brain barrier,” Dr Forrest said.

“Preventing illegal and legal plastic waste stockpiles entering the oceanic environment is critical to limit this harm. Once in the ocean, through both mixing, absorption and ingestion by animals, this plastic will officially enter the human environment.

Using artificial Intelligence and satellite data, Minderoo Foundation has produced the first-ever map of plastic waste build up. Most of our data about plastic waste comes from models and estimates. Now our understanding is informed by real data that can be used to guide solutions.

Global Plastic Watch arms governments and researchers around the world with data that can better guide effective waste management interventions, ensuring land-based waste doesn’t end up in our oceans,” Dr Forrest said. “We want to work with governments to ensure this tool can also help to support policy change where needed.”

Dr Fabien Laurier, Lead for Technology and Innovation, and Ocean Conservation at Minderoo Foundation said some of the Global Plastic Watch findings were surprising.

“We know that land-based leakage contributes up to 91 per cent of the plastic waste that enters the ocean,” Dr Laurier said. “Global Plastic Watch has revealed that many large-scale waste sites across the first 25 countries we have mapped were previously undocumented and the number of sites is much higher than expected.”

The government of Indonesia is working with Minderoo Foundation to increase its recycling capacity to double recycling rates by developing capacity for an additional one million tonnes per year by 2025.

Dr Nani Hendiarti, Deputy for Environment and Forestry Management Coordination, Coordinating Ministry for Maritime Affairs and Investment, Indonesia, congratulated Minderoo Foundation on the public launch of the Global Plastic Watch.

“Global Plastic Watch is very helpful for identifying undocumented or illegal waste dump sites in Indonesia,” Dr Hendiarti said. “That has enabled us to prioritise areas in need of better waste management policies and actions. Therefore, it plays an integral role in accelerating the government’s waste management achievements across all regions in the country.”

Indonesian National Plastic Action Partnership (NPAP) Chair, Sri Indrastuti Hadiputranto, said tackling the challenge of plastic pollution in Indonesia, like in many other places in the world is going to require a collaborative effort from the public, private and civil society sectors, and its measurement is without exception.

“Global Plastic Watch is a data aggregator and monitoring platform on plastic waste,” Ms. Hadiputranto said. “It’s a timely innovation for policymakers, practitioners and advocates that believe in the importance of evidence-based policy making to advance our goal in reducing 70 per cent of ocean leakage by 2025. I believe more data-oriented innovations like Global Plastic Watch will lead us to a more sustainable policy outcome and improving collaborations in data collections in Indonesia.”

Global Plastic Watch is a tool aimed at supporting country-level efforts to understand the magnitudes and effects of land-based plastic waste sites, to enable them to better address undocumented sites and monitor those that pose environmental and health concerns. The data is also expected to guide direct investments in waste infrastructure in the areas that need it the most.

The development of the Global Plastic Watch tool follows the Plastic Waste Makers Index released in 2021, that revealed the true scale and sources of the global plastic waste crisis.

Globally, a 30 per cent increase in the production of single-use plastic is projected over the next five years. The Minderoo Foundation No Plastic Waste initiative believes this growth in production will lead to an extra three trillion items of throwaway plastic waste by 2025.

Global Plastic Watch will continue to work with partners to refine the Artificial Intelligence model and technology to further increase its accuracy as it expands its coverage to new sites and countries throughout 2022.

Global Plastic Watch site: globalplasticwatch.org
Global Plastic Watch project site: Minderoo.org/global-plastic-watch/

LINK TO PHOTOS (Password: k3YBL4TciY) | INTERVIEWS AND B-ROLL HERE | 2:17 VIDEO EDIT WITH ENGLISH NARRATION HERE |

About Minderoo Foundation:

Established by Andrew and Nicola Forrest in 2001, Minderoo Foundation is a modern philanthropic organisation seeking to break down barriers, innovate and drive positive, lasting change. Minderoo Foundation is proudly Australian, with key initiatives spanning from ocean research and ending slavery, to collaboration against cancer and building community projects.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye